Arena Pharma (ARNA) Tops Q3 EPS by 2c

Arena Pharma (NASDAQ: ARNA) reported Q3 EPS of ($0.05), $0.02 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $19 million versus the consensus estimate of $13.99 million.

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30